Fluorouracil sustained release agent in the treatment of advanced gastric cancer
10.3969/j.issn.2095-4344.2013.42.020
- VernacularTitle:氟尿嘧啶缓释剂在进展期胃癌治疗中的应用
- Author:
Bin ZHANG
;
Bingji WANG
;
Zengcai LI
;
Xianzhong LIU
;
Xuan WANG
- Publication Type:Journal Article
- Keywords:
digestive system diseases;
stomach diseases;
neoplasms by site;
digestive system neoplasms;
stomach neoplasms
- From:
Chinese Journal of Tissue Engineering Research
2013;(42):7469-7474
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Fluorouracil sustained-release agent is a commonly used anti-cancer sustained-release drug, which has a good anti-tumor effect.
OBJECTIVE:To explore the effect of fluorouracil sustained-release agent in the treatment of gastric cancer. METHODS:Literatures concerning the effect of fluorouracil sustained-release agent in the treatment of gastric cancer were retrieved and analyzed. In the paper, we investigated the preventive effect of fluorouracil sustained-release agent against tumor recurrence and metastasis after radical resection, and fol owed up the patients who underwent clinical peritoneal implantation of fluorouracil sustained-release agent. We could determine the effect of fluorouracil sustained-release agent in the treatment of advanced gastric cancer by observing the patient’s symptoms and signs, expression of tumor markers, tumor size and survival rate.
RESULTS AND CONCLUSION:After combination therapy of fluorouracil sustained-release agent and arterial infusion chemotherapy adjuvant therapy, the patient’s symptoms and tumor resection rate were significantly improved. The levels of CEA, CA19-9, CA72-4 in the serum of patients significantly reduced, while the apoptosis and necrosis of tumor cells significantly increased. Fluorouracil sustained-release agent could also reduce tumor metastasis and local recurrence, and improve patient survival.
